Symptoms and General Pathology

All Conditions

Neoplasms

Rare Diseases

Recurrence

Carcinoma

Carcinoma, Transitional Cell

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Disease Attributes

Transitional Cell Carcinoma

Transitional Cell Cancer of the Renal Pelvis and Ureter

Antineoplastic Agents

All Drugs and Chemicals

Docetaxel

Tubulin Modulators

Antimitotic Agents

After Surgery, intravesical chemotherapy with in 48 hrs (Docetaxel 75 mg diluted in 100 cc of normal saline)

After Surgery, intravesical chemotherapy with in 48 hrs (Placebo, 100 cc of normal saline)

Intravesical Instillation of Docetaxel (Docetaxel 75 mg diluted in 100 cc of normal saline) after operation of Upper urinary tract urothelial carcinoma (With in 48 hrs)

Intravesical Instillation of Normal saline (100 cc of normal saline) after operation of Upper urinary tract urothelial carcinoma (With in 48 hrs)

Placebo Normal saline

Ja Hyeon Ku, M.D.,PH.D

Bum Sik Tae, M.D

Ja Hyeon Ku, M.D, Ph.D

The investigators evaluated the efficacy of a single early intravesical instillation of doxetaxel in the prevention of bladder recurrence after nephroureterectomy or distal ureterectomy for upper urinary tract urothelial carcinoma (UUT-UC).

Approximately 20% to 50% of patients with upper urinary tract urothelial carcinoma (UUT-UC) experience bladder recurrence after nephroureterectomy. Although many agents have been administered for the prevention of bladder recurrence, the standard prophylactic treatment has yet to be established. A meta-analysis found that a single instillation of chemotherapy immediately after transurethral resection of bladder tumor (TURBT) significantly decreased the risk of recurrence in patients with bladder cancer. Indeed, a single early instillation of Docetaxel was found to reduce the post-TURBT bladder recurrence rate among patients with bladder cancer.

In this prospective, randomized study, the investigators evaluated the efficacy of a single, early, intravesical instillation of Docetaxel in the prevention of bladder recurrence after nephroureterectomy for UUT-UC.

The Effectiveness and Safety of Intravesical Docetaxel Instillation for Prevent Bladder Recurrence

The Effectiveness and Safety of Intravesical Docetaxel Instillation After Operation to Prevent Intravesical Recurrence After Radical Nephroureterectomy or Distal Ureterectomy in Upper Urinary Tract Urothelial Carcinoma: A Prospective Study

Present of bladder recurrence after intervention in follow up cystoscopy or CT scan

Present of adverse event after intervention

Overall Survival rate during follow up period

Time to bladder recurrence after intervention in follow up cystoscopy or CT scan

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
The Effectiveness and Safety of Intravesical Docetaxel Instillation for Prevent Bladder Recurrence	NCT03209206	Urothelial Carc...	Docetaxel Placebo Normal ...	19 Years - 85 Years	Seoul National University Hospital
The Effectiveness and Safety of Intravesical Docetaxel Instillation for Prevent Bladder Recurrence	NCT03209206	Urothelial Carc...	Docetaxel Placebo Normal ...	19 Years - 85 Years	Seoul National University Hospital

Spots Global Cancer Trial Database for placebo normal saline